Acasti Pharma Inc. (NASDAQ:ACST – Get Rating) – Equities researchers at Oppenheimer dropped their FY2026 earnings estimates for Acasti Pharma in a research report issued to clients and investors on Wednesday, June 22nd. Oppenheimer analyst L. Gershell now forecasts that the biopharmaceutical company will post earnings of $0.19 per share for the year, down from their previous estimate of $0.25. The consensus estimate for Acasti Pharma’s current full-year earnings is ($0.71) per share.
Separately, StockNews.com upgraded shares of Acasti Pharma to a “sell” rating in a research report on Monday, March 14th.
An institutional investor recently bought a new position in Acasti Pharma stock. Two Sigma Securities LLC purchased a new position in Acasti Pharma Inc. (NASDAQ:ACST – Get Rating) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 13,370 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Two Sigma Securities LLC owned approximately 0.05% of Acasti Pharma at the end of the most recent quarter. 0.46% of the stock is currently owned by hedge funds and other institutional investors.
Acasti Pharma Company Profile (Get Rating)
Acasti Pharma Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia.
- Get a free copy of the StockNews.com research report on Acasti Pharma (ACST)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.